Pharvaris Reports Earnings Days After Pricing a Hundred Million Dollar Offering

Pharvaris N.V. (NASDAQ: PHVS) is scheduled to report first-quarter 2026 earnings on May 12, 2026, with analysts expecting a loss of $0.76 per share. The central question for investors is whether the clinical-stage biotech can demonstrate progress in its hereditary angioedema (HAE) pipeline while managing cash burn—a critical balance as the company advances its lead oral therapy toward potential commercialization. With the stock trading near recent highs and analyst sentiment overwhelmingly bullish, this report will test whether operational momentum can justify elevated expectations.

Part 1: Earnings Preview

Pharvaris is a clinical-stage biopharmaceutical company focused on developing novel oral therapies for rare bradykinin-driven diseases, with its lead candidate PHA121—a once-daily oral plasma kallikrein inhibitor—targeting prophylactic treatment of hereditary angioedema (HAE). The company operates in the rare disease space where unmet medical needs create significant commercial opportunities for effective therapies.

Pharvaris will report Q1 2026 results on May 12, 2026, with the consensus estimate calling for a loss of $0.76 per share from 6 analysts. The company most recently reported Q4 2025 results with an actual loss of $0.84 per share. Compared to the same quarter last year (Q1 2025), when Pharvaris posted a loss of $0.89 per share, the current estimate of ($0.76) represents a 14.61% improvement year-over-year—signaling analysts expect modestly narrowing losses as the company progresses through clinical development.

Three key themes define this earnings story:

Clinical Trial Progress and Regulatory Milestones: Investors will scrutinize any updates on PHA121's clinical development timeline, enrollment rates, and potential regulatory interactions. Recent analyst coverage from Wolfe Research (initiated with Outperform, $42 target) and Wedbush (raised target to $42) suggests optimism around the program's advancement, making any concrete progress updates critical to maintaining momentum.

Cash Runway and Burn Rate Management: With consensus estimates projecting losses of $3.19 per share for full-year 2026, cash management remains paramount. HC Wainwright's recent note maintained a $60 price target while adjusting near-term EPS estimates, reflecting the delicate balance between funding clinical operations and extending runway. Any commentary on capital allocation or financing plans will be closely watched.

Long-Term Profitability Path: HC Wainwright's materially raised FY2029 EPS forecast to $1.64 (from prior estimates) signals growing confidence in the commercial opportunity. However, Royal Bank of Canada's more cautious stance (target cut from $52 to $51) reminds investors that execution risk remains. The earnings call will be scrutinized for management's confidence in the path from clinical development to revenue generation.

Ahead of the release, Wolfe Research initiated coverage with an Outperform rating and $42 target, citing the HAE market opportunity, while Wedbush raised its target to $42, echoing institutional optimism. However, HC Wainwright's recent adjustments—lowering Q1 2026 estimates from ($0.80) to ($0.83) while maintaining a Buy rating and $60 target—suggest near-term expense pressures may weigh on results even as the long-term thesis strengthens.

Part 2: Historical Earnings Performance

Pharvaris has demonstrated a mixed but improving earnings track record over the past four quarters. The company missed estimates in three of the four most recent quarters, with misses of 11.25% in Q1 2025 (reported $0.89 vs. $0.80 estimate), 8.05% in Q2 2025 (reported $0.94 vs. $0.87 estimate), and an unavailable comparison in Q4 2025 due to lack of consensus estimate. The lone bright spot came in Q3 2025, when Pharvaris beat by 10.26% (reported $0.70 vs. $0.78 estimate)—the company's best performance in the recent period.

The pattern reveals volatility in expense management and forecasting accuracy, typical of clinical-stage biotechs where R&D spending can fluctuate with trial timelines. The Q3 2025 beat suggests the company may have achieved operational efficiencies or timing benefits, but the subsequent Q4 2025 result of ($0.84)—worse than the Q3 outcome—indicates expenses remain lumpy. The sequential deterioration from Q3 to Q4 (from $0.70 to $0.84 loss) raises questions about whether cost controls can be sustained.

Looking at the year-over-year trend, losses have modestly improved from ($0.89) in Q1 2025 to the current Q1 2026 estimate of ($0.76), representing a 14.61% reduction. This gradual improvement aligns with a company advancing through clinical stages without yet generating revenue, where the focus is on controlled burn rate rather than profitability. However, the recent pattern of misses suggests analysts may still be underestimating near-term expenses, making the Q1 2026 estimate of ($0.76) a meaningful test of whether management can deliver on tightened cost guidance.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Pharvaris typically reports earnings before market open, meaning Day 0 represents the first full trading session where investors react to results, while Day +1 captures follow-through momentum.

Historical price behavior shows significant volatility around earnings releases, with an average absolute Day 0 move of 4.91% and Day +1 move of 4.55%. The stock has exhibited wide intraday ranges, averaging 7.77% on Day 0 and 8.88% on Day +1, reflecting the binary nature of clinical-stage biotech reactions where investor sentiment can swing sharply on trial updates or guidance changes.

The directional pattern is mixed but skewed negative on initial reactions. Recent reports show Day 0 declines in four of the last five quarters, including a 7.49% drop in April 2025 and a 7.55% decline in August 2024. However, Day +1 often brings reversals—most notably in August 2024 when a 7.55% Day 0 decline was followed by a 13.55% Day +1 surge, suggesting initial overreactions are frequently corrected as investors digest details.

The November 2025 report stands out with a 7.01% Day 0 gain followed by a 6.01% Day +1 decline, demonstrating how positive surprises can trigger profit-taking. The most recent April 2026 report showed relative stability with a 3.02% Day 0 decline and modest 0.67% Day +1 follow-through, potentially indicating the market is becoming more measured in its reactions as the company matures. Investors should prepare for a 5–9% potential move in either direction based on whether results and commentary exceed or disappoint expectations, with particular sensitivity to any clinical timeline updates or cash runway guidance.

Part 2.2: Options Market Expected Move

The options market is pricing an 8.37% expected move through the May 15th expiration (4 days away), which is notably higher than the stock's average historical Day 0 move of 4.91% but roughly in line with the average Day +1 move of 4.55%. This suggests options traders are anticipating above-average volatility for this particular release, potentially reflecting heightened uncertainty around clinical updates or cash guidance that could drive larger-than-typical swings.

Part 3: What Analysts Are Saying

Analyst sentiment on Pharvaris is overwhelmingly bullish, with the stock carrying an average recommendation of 4.62 out of 5.0—firmly in Strong Buy territory. The consensus is supported by 10 Strong Buy ratings and 1 Moderate Buy, balanced against just 2 Hold ratings and zero sell recommendations among 13 analysts covering the stock. This lopsided bullish stance reflects broad confidence in the company's HAE pipeline and commercial potential.

The average price target of $47.17 implies 57% upside from the current price of $30.00, with a wide range spanning from a low target of $30.00 (essentially at current levels) to a high of $75.00 (150% upside). The breadth of this range—$45 between low and high—underscores the uncertainty inherent in valuing a pre-revenue biotech, where outcomes are heavily dependent on clinical and regulatory milestones. The mean target suggests analysts see substantial value creation ahead if execution continues.

Sentiment has remained unchanged over the past month, with rating counts and the average recommendation holding steady at 4.62. This stability follows a period of strengthening conviction, as the Barchart Opinion signal improved from 56% Buy a month ago to 100% Buy currently. Recent analyst actions support this momentum: Wolfe Research's April initiation at Outperform with a $42 target and Wedbush's target raise to $42 signal fresh institutional validation, while HC Wainwright's maintained $60 target (despite near-term EPS adjustments) reflects sustained long-term optimism. The lack of downgrades or negative revisions suggests the analyst community is aligned on the risk-reward profile heading into this report.

Part 4: Technical Picture

Pharvaris enters earnings with strong technical momentum, as the Barchart Technical Opinion currently stands at 100% Buy—a significant strengthening from 56% Buy one month ago and matching last week's 100% Buy reading. This rapid improvement in the signal reflects accelerating bullish momentum as the stock has climbed steadily into the release.

Timeframe Analysis:

• Short-term (100% Buy): Strong buy signal indicates robust near-term momentum with buyers in control heading into the earnings event
• Medium-term (100% Buy): Continued strength in the intermediate timeframe suggests the uptrend is well-established beyond just short-term positioning
• Long-term (100% Buy): Bullish long-term signal confirms the stock is in a sustained uptrend across all major time horizons

Trend Characteristics: The trend is characterized as Strong and Strengthening, indicating not only that the stock is in a clear uptrend but that momentum is accelerating—a supportive technical backdrop for an earnings release where positive surprises could fuel further gains.

The stock is trading at $30.00, positioned above all key moving averages: the 5-day ($29.98), 10-day ($29.84), 20-day ($29.32), 50-day ($27.89), 100-day ($27.22), and 200-day ($25.21). This complete alignment with the stock above every major moving average is a textbook bullish setup, indicating strong support at multiple levels and suggesting any earnings-related pullback would likely find buyers at these technical floors.

The 200-day moving average at $25.21 represents the most significant long-term support level, now 16% below the current price, providing a substantial cushion. More immediately, the 20-day moving average at $29.32 serves as near-term support just 2.3% below current levels, likely acting as the first line of defense if results disappoint. The stock's position at the upper end of its recent range—having climbed from a 52-week low of $14.59 to approach the $31.14 high—suggests limited overhead resistance but also raises the stakes for this report, as any disappointment could trigger profit-taking from recent buyers. Overall, the technical setup is highly supportive heading into earnings, with momentum, trend alignment, and moving average structure all favoring bulls—though the elevated positioning means the stock has priced in considerable optimism that management must now validate.